46. Malignant rheumatoid arthritis Clinical trials / Disease details
Clinical trials : 4,325 / Drugs : 2,671 - (DrugBank : 417) / Drug target genes : 187 - Drug target pathways : 224
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02936180 (ClinicalTrials.gov) | October 2016 | 7/10/2016 | Standard Versus High Dose Inactivated Influenza Vaccine in RA | Improving Influenza Immunization Responses in Rheumatoid Arthritis: A Strategy To Enhance Protection Against A Preventable Cause Of Death In An At Risk Population? | Rheumatoid Arthritis | Biological: HD-TIV;Biological: SD-QIV | McGill University Health Centre/Research Institute of the McGill University Health Centre | The Arthritis Society, Canada | Unknown status | 18 Years | N/A | All | 280 | Phase 4 | Canada |